Free Shipping on orders over $150
Awaiting product image

Tesamorelin — 5mg

Synthetic GHRH Analog / Extended Half-Life

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog peptide represented by 122 indexed PubMed research records, including 24 clinical studies.

$55.00

Tesamorelin (Egrifta / Egrifta SV / Egrifta WR) is the only peptide with full FDA approval for visceral fat reduction, specifically in HIV-associated lipodystrophy. Approved 2010

Premium Subscribers only. This compound is part of the restricted catalog. Become a Premium subscriber to purchase.
SKU: LL-TESA Category:

PubMed Literature Index

122

studies indexed in the public literature

Q2 2026 · view PubMed search ↗

101
Human
104
Animal
24
Clinical Trials
0
EU Trials

Overview

Studies describe Tesamorelin as a GHRH analog carrying a trans-3-hexenoic acid modification at the N-terminus, a structural change reported to substantially extend its half-life relative to earlier GHRH analogs such as Sermorelin (approximately 26 minutes versus roughly 10 minutes). The literature identifies it as the only GHRH analog with FDA approval for clinical use, marketed under the name Egrifta for HIV-associated lipodystrophy. Within that research base, the most consistently reported finding is targeted reduction of visceral adipose tissue, with an evidence base described in the literature as exceeding that of other compounds in the GH secretagogue class.

Chemical & Molecular Properties

FormulaC221H366N72O67S
Mol. Weight5136 g/mol
PubChem CID16137828

Key Areas of Research Interest

  • Investigated in the context of GHRH receptor activation and pulsatile growth hormone secretion
  • Investigated in the context of visceral adipose tissue reduction in HIV-associated lipodystrophy research
  • Investigated in the context of extended-duration GHRH analog design, compared against earlier secretagogues such as Sermorelin
  • Investigated within a substantial clinical research base (24 indexed clinical studies) relative to other compounds in the GH secretagogue class

FAQ

What is Tesamorelin commonly researched for?

Tesamorelin is studied in laboratory research as a GHRH analog investigated for its role in growth hormone secretion pathways, with a substantial clinical literature base examining visceral fat reduction in HIV-associated lipodystrophy contexts. This research is conducted in laboratory and preclinical settings only.

Is Tesamorelin FDA-approved?

No. Sold for laboratory research use only, not FDA-approved, not for human or veterinary consumption.

How is Tesamorelin stored?

Tesamorelin is stored lyophilized and frozen, protected from light; refrigerated after reconstitution for research use.

What purity standard does Legendary Labz hold Tesamorelin to?

Legendary Labz holds Tesamorelin to a third-party-tested purity standard; every lot is independently tested to verify identity and purity.

Is a Certificate of Analysis available for Tesamorelin?

Certificates of Analysis for Tesamorelin are published per lot as testing completes.

Materials referenced on this page are intended for laboratory research purposes. No claims regarding therapeutic efficacy are made or implied. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.

Description

Overview

Tesamorelin (Egrifta / Egrifta SV / Egrifta WR) is the only peptide with full FDA approval for visceral fat reduction, specifically in HIV-associated lipodystrophy. Approved 2010 following two Phase III RCTs (GROW1/GROW2, n=816) demonstrating 15-20% VAT reduction at 26 weeks. An F8 formulation (EGRIFTA WR) was approved November 2023, requiring only weekly reconstitution instead of daily preparation, improving adherence significantly. Important scope limitation: FDA approval is for HIV lipodystrophy only, not general obesity or metabolic syndrome. Off-label visceral fat use is at physician discretion. 2024 studies extended evidence to cognitive function (executive function/memory improvement vs. placebo in HIV patients) and NAFLD liver fat reduction. Anti-tesamorelin IgG antibodies develop in up to 56% of patients at 26 weeks, with ~60% cross-reactivity to endogenous GHRH, monitor for hypersensitivity reactions.

Structure & Chemistry

  • Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
  • Category: GROWTH HORMONE / VISCERAL FAT
  • Molecular size: 5,136.0 Da (44-amino-acid GHRH analog with trans-3-hexenoic acid)

Regulatory & Research Status

  • FDA: APPROVED as Egrifta / Egrifta SV / Egrifta WR, but ONLY for HIV-associated lipodystrophy (visceral fat). NOT approved for general weight loss, obesity, or anti-aging. Off-label use is at physician discretion.
  • WADA: Prohibited S2 (GHRH Analogs), banned in and out of competition for all tested athletes.
  • Evidence tier: Strongest in GH Axis section, Phase III RCT data (n=816), FDA-reviewed. Cognitive and NAFLD data is 2024 HIV-population studies; not yet validated for general population.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category GROWTH HORMONE / VISCERAL FAT
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin — 5mg”

Your email address will not be published. Required fields are marked *

Overview

Tesamorelin (Egrifta / Egrifta SV / Egrifta WR) is the only peptide with full FDA approval for visceral fat reduction, specifically in HIV-associated lipodystrophy. Approved 2010 following two Phase III RCTs (GROW1/GROW2, n=816) demonstrating 15-20% VAT reduction at 26 weeks. An F8 formulation (EGRIFTA WR) was approved November 2023, requiring only weekly reconstitution instead of daily preparation, improving adherence significantly. Important scope limitation: FDA approval is for HIV lipodystrophy only, not general obesity or metabolic syndrome. Off-label visceral fat use is at physician discretion. 2024 studies extended evidence to cognitive function (executive function/memory improvement vs. placebo in HIV patients) and NAFLD liver fat reduction. Anti-tesamorelin IgG antibodies develop in up to 56% of patients at 26 weeks, with ~60% cross-reactivity to endogenous GHRH, monitor for hypersensitivity reactions.

Structure & Chemistry

  • Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
  • Category: GROWTH HORMONE / VISCERAL FAT
  • Molecular size: 5,136.0 Da (44-amino-acid GHRH analog with trans-3-hexenoic acid)

Regulatory & Research Status

  • FDA: APPROVED as Egrifta / Egrifta SV / Egrifta WR, but ONLY for HIV-associated lipodystrophy (visceral fat). NOT approved for general weight loss, obesity, or anti-aging. Off-label use is at physician discretion.
  • WADA: Prohibited S2 (GHRH Analogs), banned in and out of competition for all tested athletes.
  • Evidence tier: Strongest in GH Axis section, Phase III RCT data (n=816), FDA-reviewed. Cognitive and NAFLD data is 2024 HIV-population studies; not yet validated for general population.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category GROWTH HORMONE / VISCERAL FAT
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Related Research

Related products